| Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma T Powles, SH Park, E Voog, C Caserta, BP Valderrama, H Gurney, ... New England Journal of Medicine 383 (13), 1218-1230, 2020 | 995 | 2020 |
| American Cancer Society prostate cancer survivorship care guidelines TA Skolarus, AMD Wolf, NL Erb, DD Brooks, BM Rivers, W Underwood III, ... CA: a cancer journal for clinicians 64 (4), 225-249, 2014 | 430 | 2014 |
| Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel ER Gardner, WL Dahut, CD Scripture, J Jones, JB Aragon-Ching, N Desai, ... Clinical Cancer Research 14 (13), 4200-4205, 2008 | 270 | 2008 |
| Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised … DP Petrylak, R De Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, ... The Lancet 390 (10109), 2266-2277, 2017 | 239 | 2017 |
| A phase II clinical trial of sorafenib in androgen-independent prostate cancer WL Dahut, C Scripture, E Posadas, L Jain, JL Gulley, PM Arlen, JJ Wright, ... Clinical cancer research 14 (1), 209-214, 2008 | 208 | 2008 |
| ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel TM Sissung, CE Baum, J Deeken, DK Price, J Aragon-Ching, ... Clinical cancer research 14 (14), 4543-4549, 2008 | 170 | 2008 |
| Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy NS Azad, JB Aragon-Ching, WL Dahut, M Gutierrez, WD Figg, L Jain, ... Clinical Cancer Research 15 (4), 1411-1416, 2009 | 167 | 2009 |
| Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents JB Aragon-Ching, YM Ning, CC Chen, L Latham, JP Guadagnini, ... Cancer investigation 27 (2), 221-226, 2009 | 167 | 2009 |
| Role of chemotherapy in prostate cancer R Nader, J El Amm, JB Aragon-Ching Asian journal of andrology 20 (3), 221-229, 2018 | 147 | 2018 |
| Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer JB Aragon-Ching, KM Williams, JL Gulley Front Biosci 12 (4957), 71, 2007 | 147 | 2007 |
| Clinical cancer advances 2017: annual report on progress against cancer from the American Society of Clinical Oncology HJ Burstein, L Krilov, JB Aragon-Ching, NN Baxter, EG Chiorean, ... Journal of Clinical Oncology 35 (12), 1341-1367, 2017 | 143 | 2017 |
| Final analysis of a phase II trial using sorafenib for metastatic castration‐resistant prostate cancer JB Aragon‐Ching, L Jain, JL Gulley, PM Arlen, JJ Wright, SM Steinberg, ... BJU international 103 (12), 1636-1640, 2009 | 135 | 2009 |
| CNS metastasis: an old problem in a new guise JB Aragon-Ching, JA Zujewski Clinical Cancer Research 13 (6), 1644-1647, 2007 | 115 | 2007 |
| Maintenance avelumab+ best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 … T Powles, SH Park, E Voog, C Caserta, BP Valderrama, H Gurney, ... Journal of Clinical Oncology 38 (18_suppl), LBA1-LBA1, 2020 | 105 | 2020 |
| Vitamin D in prostate cancer DL Trump, JB Aragon-Ching Asian journal of andrology 20 (3), 244-252, 2018 | 93 | 2018 |
| Thalidomide analogues as anticancer drugs JB Aragon-Ching, H Li, ER Gardner, WD Figg Recent patents on anti-cancer drug discovery 2 (2), 167-174, 2007 | 88 | 2007 |
| Docetaxel as monotherapy or combined with ramucirumab or icrucumab in second-line treatment for locally advanced or metastatic urothelial carcinoma: an open-label, three-arm … DP Petrylak, ST Tagawa, M Kohli, A Eisen, C Canil, SS Sridhar, A Spira, ... J Clin Oncol 34 (13), 1500-1509, 2016 | 82 | 2016 |
| VEGF inhibitors and prostate cancer therapy JB Aragon-Ching, WL Dahut Current molecular pharmacology 2 (2), 161-168, 2009 | 79 | 2009 |
| The changing landscape in the treatment of metastatic castration-resistant prostate cancer J El-Amm, JB Aragon-Ching Therapeutic advances in medical oncology 5 (1), 25-40, 2013 | 64 | 2013 |
| Role of chemotherapy and mechanisms of resistance to chemotherapy in metastatic castration-resistant prostate cancer V Lohiya, JB Aragon-Ching, G Sonpavde Clinical Medicine Insights: Oncology 10, CMO. S34535, 2016 | 62 | 2016 |
